Form 4 for NAMS NewAmsterdam Pharma Co N.V.
Accepted 2026-09-09 16:30:03 ET · period of report 2026-09-04 · accession 0001193125-26-386508 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-09 16:30 | 2026-09-04 | NAMS | Smither John W | Dir | S - Sale | $25.32 | -1,600 | 8,760 | -15% | -$40.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-09-04 | S | D | 1,600 | $25.32 | 8,760 | D | — | — | (F1) Reported transaction reflects a sale of ordinary shares to generate proceeds to satisfy the Reporting Person's tax obligations in connection with the prior vesting of restricted stock units. (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.24 to $25.37 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. (F3) Includes 8,040 ordinary shares subject to restricted stock unit awards that remain subject to vesting. |